OCTP announces breakthrough in cancer immunotherapy
LONDON, UK: Oxford Cannabinoid Technologies Holdings plc (OCTP), a leading pharmaceutical company in the field of cannabinoid medicines, has revealed a promising new drug candidate for the treatment of solid tumours. The drug, which is derived from OCTP’s proprietary library of cannabinoid compounds, has shown remarkable potency and selectivity in targeting a key immune checkpoint…